Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOLIFE2: MaaT033 and Cemiplimab vs Investigator's Choice in ICI-Resistant Advanced NSCLC
NCT07001618Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Nov 2025
- Primary completion
- Sep 2030
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of MaaT-033 in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Started Nov 2025; status: recruiting.
02
Drugs
MaaT-033
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07001618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001618.